A slow, steady upward climb is what I expected and continue to expect.
As the smart money reads the tea leaves (publicly available data on MNTA's FDA application/ data from the extensive legal record/ the steep wall faced by other generic copaxone applications), I think it inevitable that they will see this stock as tremendously undervalued. It won't remain that way.
The immediate post-approval 'pop' was understandably undercut by disappointed longs running for the exits -- but will still going to occur. A fresh look by smart eyes will lift this stock much higher.
MNTA's debacle following the Lovenox approval is one that they've learned from. This is a different product. Sometimes the past doesn't even rhyme with the future.
Market Data 
Markets 
AI
